Medicine

All Articles

Human episodes of an unfamiliar reassortant Oropouche virus in the Brazilian Amazon location

.Attributes Medicine, Released online: 18 September 2024 doi:10.1038/ s41591-024-03300-3Genomic and ...

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative boob cancer cells: a period 2 adaptive test

.PatientsPatients in associates An and B were actually eligible for registration if they went to lea...

Targeted therapy assisted through circulating growth DNA review in innovative intestinal lumps

.Attributes Medicine, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empi...

Countering the influence of the climate dilemma on wellness will certainly call for records

.As dramatically rising international temps endanger the health and also wellness of populations, re...

Exposure to extreme warm boosts perinatal mortality in sub-Saharan Africa

.Publisheru00e2 $ s keep in mind Springer Nature remains neutral for managerial insurance claims in ...

Data- steered risk stratification as well as accuracy management of lung blemishes found on upper body calculated tomography

.Individual recruitmentThe retrospective main dataset consisted of participants from the MCC in the ...

Datopotamab\u00e2 $ \"deruxtecan in early-stage boob cancer cells: the sequential multiple job randomized I-SPY2.2 stage 2 trial

.Completing interests.J.L.M. mentions institutional analysis financing coming from AstraZeneca, Seag...

Trastuzumab deruxtecan in HER2-positive state-of-the-art breast cancer along with or even without mind metastases: a stage 3b\/4 trial

.Attributes Medication, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-r...

Advancing ASO treatments coming from development to application

.Completing rate of interests.R.S., M.S., H.G. and A.A.R. are actually organizers of the 1M1M projec...

Post- approval evidence creation: a mutual duty for healthcare

.Nature Medicine, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03241-xPost-approval proo...